Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian neurotoxin methylpyridinium ion

Journal of Neurochemistry

Volumn 71, Issue 1, 1998, Pages 295-301

  Cassarino, David S ^a   Fall, Christopher P ^a   Smith, Trisha S ^a   Bennett Jr , James P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Mitochondria; Mitochondrial permeability transition pore; Oxygen free radicals; Parkinson's disease; Pramipexole

Indexed keywords

NEUROTOXIN; PICOLINE DERIVATIVE; PRAMIPEXOLE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MEMBRANE PERMEABILITY; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0031842356     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71010295.x     Document Type: Article

References (50)

1. Ali S. F., David S. N., Newport G. D., Cadet J. L., and Slikker W. (1994) MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine loss. Synapse 18, 27-34.
2. Beal M. F., Hyman B. T., and Koroshetz W. (1993) Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16, 125-131.
3. Bernardi P. (1996) The permeability transition pore. Control points of a CsA-sensitive mitochondrial channel involved in cell death. Biochim. Biophys. Acta 1275, 5-9.
4. Bernardi P. and Petronilli V. (1996) The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J. Bioenerg. Biomembr. 28, 131-138.
5. Bernardi P., Broekemeier K. M., and Pfeiffer D. R. (1994) Recent progress on regulation of the permeability transition pore, a cyclosporin A-sensitive pore in the mitochondrial inner membrane. J. Bioenerg. Biomembr. 26, 509-517.
6. Bindoff L. A., Birch-Machin M., Cartilidge N. E., Parker W. D., and Turnbull D. M. (1991) Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J. Neurol. Sci. 104, 203-208.
7. Bowling A. C. and Beal M. F. (1995) Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci. 56, 1151-1171.
8. Broekemeier K. M. and Pfeiffer D. R (1995) Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. Biochemistry 34, 16440-16449.
9. Burns R. S., Chiueh C. C., Markey S. P., Ebert M. H., Jacobowitz D. M., and Kopin I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
10. Cassarino D. S., Fall C. P., Swerdlow R. H., Smith T. S., Halvorsen E. M., Miller S. M., Parks J. P., Parker W. D. Jr., and Bennett J. P. Jr. (1997) Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362, 77-86.
11. Chernyak V. and Bernardi P. (1996) The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur. J. Biochem. 238, 623-630.
12. Connern C. P. and Halestrap A. P. (1994) Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of a calcium-sensitive non-specific channel. Biochem. J. 302, 321-324.
13. Constantini P., Petronilli V., Colonna R., and Bernardi P. (1995) On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. Toxicology 99, 77-88.
14. Dipasquale B., Marini A. M., and Youle R. J. (1991) Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem. Biophys. Res. Commun. 181, 1442-1448.
15. Gunasekar P. G., Kanthasamy J. L., Borowitz J. L., and Isom G. E. (1995) Monitoring intracellular nitric oxide formation by dichlorofluorescin in neuronal cells. J. Neurosci. Methods 61, 15-21.
16. Hall E. D., Andrus P. K., Oostveen J. A., Althaus J. S., and Von-Voigtlander P. F. (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742, 80-88.
17. Kaur H., Whiteman M., and Halliwell B. (1997) Peroxynitrite-dependent aromatic hydroxylation and nitration of salicylate and phenylalanine. Is hydroxyl radical involved? Free Radic. Res. 26, 71-82.
18. Kondo T. (1996) Parkinson's disease and free radicals. Mechanisms of neurodegeneration and neuroprotection. Ann. NY Acad. Sci. 786, 206-216.
19. 2+-induced mitochondrial membrane permeabilization: role of co-enzyme Q redox state. Am. J. Physiol. 269, C141-C147.
20. 2+ is depen-dent on mitochondrial-generated reactive oxygen species. FEBS Lett. 378, 150-152.
21. Kristal B. S. and Dubinsky J. M. (1997) Mitochondrial permeability transition in the central nervous system: induction by calcium cycling-dependent and -independent pathways. J. Neurochem. 69, 524-538.
22. Langston J. W., Ballard P., Tetrud J. W., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
23. Mann V. M., Cooper J. M., Kriige D., Daniel S. E., Schapira A. H. V., and Marsden D. (1992) Brain, skeletal muscle, and platelet homogenate mitochondrial functions in Parkinson's disease. Brain 115, 333-342.
24. Marchetti P., Castedo M., Zamzani N., Hirsch T., Haeffner A., Geuskens M., and Kroemer G. (1996) Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med. 184, 1155-1160.
25. Markesberry W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147.
26. Mierau J., Schneider F. J., Ensinger H. A., Chio C. L., Lajiness M. E., and Huff R. M. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol. 290, 29-36.
27. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., and Kagawa Y. (1989) Deficiencies of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163, 1450-1455.
28. + in ventral mesencephalic-striatal coculture in rat. Neurosci. Lett. 170, 191-194.
29. Mytilineou C., Werner P., Molinari S., DiRocco A., Cohen G., and Yahr M. D. (1994) Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 8, 223-228.
30. +, a metabolite of the neurotoxin, MPTP. Life Sci. 36, 2503-2508.
31. + and nitric oxide simultaneously causes CsA-sensitive mitochondrial calcium efflux and depolarization. Biochem. Pharmacol. 51, 267-273.
32. Parker W. D. Jr., Boyson S. J., and Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
33. + and beta amyloid peptide. Soc. Neurosci. Abstr. 23, 1907.
34. Pastorino J. G., Snyder J. W., Serroni A., Hoek J. B., and Farber J. L. (1993) Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J. Biol. Chem. 268, 13791-13798.
35. 2+ depletion prevents anoxic death of hepatocytes by inhibiting mitochondrial permeability transition. Am. J. Physiol. 268, C676-C685.
36. Piercey M. F., Hoffmann W. E., Smith M. W., and Hyslop D. K. (1996) Inhibition of dopamine neuron firing by pramipexole, a D3-preferring dopamine agonist: comparison to other dopamine agonists. Eur. J. Pharmacol. 312, 35-44.
37. Piercey M. F., Hyslop D. K., and Hoffmann W. E. (1997) Excitation of type II anterior caudate neurons by stimulation of D3 receptors. Brain Res. 762, 19-28.
38. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L., and Dawson T. M. (1996) Role of neuronal nitric oxide in MPTP-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA 93, 4565-4571.
39. 2 in cultured endothelial cells. Arch. Biochem. Biophys. 302, 348-355.
40. Schulz J. B., Matthews R. T., Muqit M. M. K., Browne S. E., and Beal M. F. (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939.
41. Sheehan J. P., Swerdlow R. H., Parker W. D., Miller S. W., Davis R. E., and Tuttle J. B. (1997) Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68, 1221-1233.
42. Simonian N. A. and Coyle J. T. (1996) Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36, 83-106.
43. Singer T. P. and Ramsay R. R. (1990) Mechanisms of the neurotoxicity of MPTP. FEBS Lett. 274, 1-8.
44. + -induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 5, 2598-2600.
45. +. Biochem. Pharmacol. 44, 833-835.
46. Swerdlow R. H., Parks J. K., Miller S. W., Tuttle J. B., Trimmer P. A., Sheehan J. P., Bennett J. P. Jr., Davis R. E., and Parker W. D. Jr. (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663-671.
47. Swerdlow R. H., Parks J. K., Cassarino D. S., Maguire D. J., Maguire R. S., Bennett J. P. Jr., Davis R. E., and Parker W. D. Jr. (1997) Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology 49, 918-925.
48. Zamzani N., Susin S. A., Marchetti P., Hirsch T., Gomez-Monterrey I., Casteda M., and Kroemer G. (1996) Mitochondrial control of nuclear apoptosis. J. Exp. Med. 183, 1533-1544.
49. Zhu H., Bannenber G. L., Moldeus P., and Shertzer H. G. (1994) Oxidation pathways for the intracellular probe 2′,7′-dichlorofluorescin. Arch. Toxicol. 68, 582-587.
50. Zoratti M. and Szabo I. (1995) The mitochondrial permeability transition. Biochim. Biophys. Acta 1241, 139-176.